Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 236
Filtrar
1.
Int J Antimicrob Agents ; 63(6): 107176, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38642811

RESUMO

OBJECTIVES: Optimising blood culture processing is important to ensure that bloodstream infections are accurately diagnosed while minimising adverse events caused by antibiotic abuse. This study aimed to evaluate the impact of optimised blood culture processes on antibiotic use, clinical outcomes and economics in intensive care unit (ICU) patients with positive blood cultures. METHODS: From March 2020 to October 2021, this microbiology laboratory implemented a series of improvement measures, including the clinical utility of Fastidious Antimicrobial Neutralization (FAN® PLUS) bottles for the BacT/Alert Virtuo blood culture system, optimisation of bottle reception, graded reports and an upgraded laboratory information system. A total of 122 ICU patients were included in the pre-optimisation group from March 2019 to February 2020, while 179 ICU patients were included in the post-optimisation group from November 2021 to October 2022. RESULTS: Compared with the pre-optimisation group, the average reporting time of identification and antimicrobial sensitivity was reduced by 16.72 hours in the optimised group. The time from admission to targeted antibiotic therapy within 24 hours after receiving both the Gram stain report and the final report were both significantly less in the post-optimisation group compared with the pre-optimisation group. The average hospitalisation time was reduced by 6.49 days, the average antimicrobial drug cost lowered by $1720.85 and the average hospitalisation cost by $9514.17 in the post-optimisation group. CONCLUSIONS: Optimising blood culture processing was associated with a significantly increased positive detection rate, a remarkable reduction in the length of hospital stay and in hospital costs for ICU patients with bloodstream infections.


Assuntos
Antibacterianos , Hemocultura , Estado Terminal , Unidades de Terapia Intensiva , Humanos , Hemocultura/métodos , Hemocultura/economia , Masculino , Feminino , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Antibacterianos/economia , Idoso , Bacteriemia/diagnóstico , Bacteriemia/tratamento farmacológico , Bacteriemia/economia , Bacteriemia/microbiologia , Adulto , Tempo de Internação , Testes de Sensibilidade Microbiana/economia , Testes de Sensibilidade Microbiana/métodos
2.
Cancer Control ; 28: 10732748211045593, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34558349

RESUMO

OBJECTIVES: Vancomycin-resistant enterococcus infections impact mortality in oncology patients. Given the low rate of vancomycin-resistant enterococcus bacteremia, low virulence of vancomycin-resistant enterococcus, and advent of rapid diagnostic systems, vancomycin-resistant enterococcus-directed empiric therapy in vancomycin-resistant enterococcus-colonized patients with neutropenic fever may be unnecessary, promoting increased antimicrobial resistance, drug-related toxicity, and cost. METHODS: Vancomycin-resistant enterococcus-colonized adults admitted for hematopoietic stem cell transplantation or induction therapy for acute leukemia/myeloid sarcoma with neutropenic fever were stratified by vancomycin-resistant enterococcus bacteremia development and empiric vancomycin-resistant enterococcus-directed antimicrobial strategy for first neutropenic fever (Empiric Therapy vs. non-Empiric Therapy). Primary endpoints included vancomycin-resistant enterococcus-related, in-hospital, and 100-day mortality rates. Secondary outcomes included vancomycin-resistant enterococcus bacteremia incidence for first neutropenic fever and the entire hospitalization, length of stay, Clostridioides difficile infection rate, and duration and cost of vancomycin-resistant enterococcus-directed therapy. RESULTS: During first neutropenic fever, 3 of 70 eligible patients (4%) developed vancomycin-resistant enterococcus bacteremia. Although all 3 (100%) were non-Empiric Therapy, no mortality (0%) occurred. Of 67 patients not developing vancomycin-resistant enterococcus bacteremia, 42 (63%) received Empiric Therapy and 25 (37%) non-Empiric Therapy. Empiric Therapy had significantly greater median duration (3 days vs. 0 days; P<.001) and cost ($1604 vs. $0; P<.001) of vancomycin-resistant enterococcus-directed therapy but demonstrated no significant differences in clinical outcomes. CONCLUSION: Available data suggest Empiric Therapy may offer no clinical benefit to this population, regardless of whether vancomycin-resistant enterococcus is identified in blood culture or no pathogen is found. Such an approach may only expose the majority of patients to unnecessary vancomycin-resistant enterococcus-directed therapy and drug-related toxicities while increasing institutional drug and monitoring costs. Even in the few patients developing vancomycin-resistant enterococcus bacteremia, waiting until the organism is identified in culture to start directed therapy likely makes no difference in mortality. This lack of benefit warrants consideration to potentially omit empiric vancomycin-resistant enterococcus-directed therapy in first neutropenic fever in many of these patients.


Assuntos
Antibacterianos/uso terapêutico , Neutropenia Febril/complicações , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/etiologia , Resistência a Vancomicina , Adulto , Idoso , Antibacterianos/administração & dosagem , Gestão de Antimicrobianos/organização & administração , Bacteriemia/tratamento farmacológico , Bacteriemia/economia , Bacteriemia/epidemiologia , Bacteriemia/etiologia , Índice de Massa Corporal , Infecções por Clostridium/epidemiologia , Enterococcus , Feminino , Infecções por Bactérias Gram-Positivas/economia , Infecções por Bactérias Gram-Positivas/epidemiologia , Gastos em Saúde , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Fatores Sociodemográficos
3.
BMC Infect Dis ; 21(1): 572, 2021 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-34126951

RESUMO

BACKGROUND: Urinary tract infections (UTIs) are the most common infections caused by Gram-negative bacteria and represent a major healthcare burden. Carbapenem-resistant (CR) strains of Enterobacterales and non-lactose fermenting pathogens further complicate treatment approaches. METHODS: We conducted a retrospective analysis of the US Premier Healthcare Database (2014-2019) in hospitalised adults with a UTI to estimate the healthcare burden of Gram-negative CR UTIs among patients with or without concurrent bacteraemia. RESULTS: Among the 47,496 patients with UTI analysed, CR infections were present in 2076 (4.4%). Bacteraemia was present in 24.5% of all UTI patients, and 1.7% of these were caused by a CR pathogen. The most frequent CR pathogens were Pseudomonas aeruginosa (49.4%) and Klebsiella pneumoniae (14.2%). Patients with CR infections had a significantly longer hospital length of stay (LOS) (median [range] 8 [5-12] days vs 6 [4-10] days, P < 0.001), were less likely to be discharged home (38.4% vs 51.0%, P < 0.001), had a higher readmission rate (22.6% vs 13.5%, P < 0.001), and had greater LOS-associated charges (mean US$ 91,752 vs US$ 66,011, P < 0.001) than patients with carbapenem-susceptible (CS) infections, respectively. The impact of CR pathogens was greater in patients with bacteraemia (or urosepsis) and these CR urosepsis patients had a significantly higher rate of mortality than those with CS urosepsis (10.5% vs 6.0%, P < 0.001). CONCLUSIONS: Among hospitalised patients with UTIs, the presence of a CR organism and bacteraemia increased the burden of disease, with worse outcomes and higher hospitalisation charges than disease associated with CS pathogens and those without bacteraemia.


Assuntos
Carbapenêmicos/farmacologia , Farmacorresistência Bacteriana , Bactérias Gram-Negativas/fisiologia , Infecções Urinárias/economia , Infecções Urinárias/microbiologia , Idoso , Idoso de 80 Anos ou mais , Bacteriemia/economia , Bacteriemia/epidemiologia , Bacteriemia/microbiologia , Efeitos Psicossociais da Doença , Feminino , Bactérias Gram-Negativas/classificação , Hospitalização/economia , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Estados Unidos/epidemiologia , Infecções Urinárias/epidemiologia
4.
Antimicrob Resist Infect Control ; 9(1): 137, 2020 08 18.
Artigo em Inglês | MEDLINE | ID: mdl-32811557

RESUMO

BACKGROUND: Hospital-acquired bloodstream infection (BSI) is associated with high morbidity and mortality and increases patients' length of stay (LOS) and hospital charges. Our goals were to calculate LOS and charges attributable to BSI and compare results among different models. METHODS: A retrospective observational cohort study was conducted in 2017 in a large general hospital, in Beijing. Using patient-level data, we compared the attributable LOS and charges of BSI with three models: 1) conventional non-matching, 2) propensity score matching controlling for the impact of potential confounding variables, and 3) risk set matching controlling for time-varying covariates and matching based on propensity score and infection time. RESULTS: The study included 118,600 patient admissions, 557 (0.47%) with BSI. Six hundred fourteen microorganisms were cultured from patients with BSI. Escherichia coli was the most common bacteria (106, 17.26%). Among multi-drug resistant bacteria, carbapenem-resistant Acinetobacter baumannii (CRAB) was the most common (42, 38.53%). In the conventional non-matching model, the excess LOS and charges associated with BSI were 25.06 days (P < 0.05) and US$22041.73 (P < 0.05), respectively. After matching, the mean LOS and charges attributable to BSI both decreased. When infection time was incorporated into the risk set matching model, the excess LOS and charges were 16.86 days (P < 0.05) and US$15909.21 (P < 0.05), respectively. CONCLUSION: This is the first study to consider time-dependent bias in estimating excess LOS and charges attributable to BSI in a Chinese hospital setting. We found matching on infection time can reduce bias.


Assuntos
Bacteriemia/economia , Infecção Hospitalar/economia , Custos Hospitalares/estatística & dados numéricos , Pacientes Internados/estatística & dados numéricos , Tempo de Internação/economia , Adulto , Idoso , Bacteriemia/etiologia , Pequim , Infecção Hospitalar/microbiologia , Feminino , Humanos , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Centros de Atenção Terciária/economia , Centros de Atenção Terciária/estatística & dados numéricos
5.
Pediatr Blood Cancer ; 67(10): e28643, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32785971

RESUMO

BACKGROUND: Infections are common and are a major cause of morbidity and mortality during treatment of childhood leukemia. We evaluated the cost effectiveness of levofloxacin antibiotic prophylaxis, compared to no prophylaxis, in children receiving chemotherapy for acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL). PROCEDURES: A cost-utility analysis was conducted from the perspective of the single-payer health care system using a lifetime horizon. A comprehensive literature review identified available evidence for effectiveness, safety, costs of antibiotic prophylaxis in children with leukemia, and health utilities associated with the relevant health states. The effects of levofloxacin prophylaxis on health outcomes, quality-adjusted life-years (QALY), and direct health costs were derived from a combined decision tree and state-transition model. One-way deterministic and probabilistic sensitivity analyses were performed to test the sensitivity of results to parameter uncertainty. RESULTS: The literature review revealed one randomized controlled trial on levofloxacin prophylaxis in childhood AML and relapsed ALL, by Alexander et al, that showed a significant reduction in rates of fever and neutropenia (71.2% vs 82.1%) and bacteremia (21.9% vs 43.4%) with levofloxacin compared to no prophylaxis. In our cost-utility analysis, levofloxacin prophylaxis was dominant over no prophylaxis, resulting in cost savings of $542.44 and increased survival of 0.13 QALY. In probabilistic sensitivity analysis, levofloxacin prophylaxis was dominant in 98.8% of iterations. CONCLUSIONS: The present analysis suggests that levofloxacin prophylaxis, compared to no prophylaxis, is cost saving in children receiving intensive chemotherapy for AML or relapsed ALL.


Assuntos
Antibioticoprofilaxia/economia , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Bacteriemia/economia , Análise Custo-Benefício , Leucemia Mieloide Aguda/economia , Levofloxacino/economia , Leucemia-Linfoma Linfoblástico de Células Precursoras/economia , Antibacterianos/economia , Antibacterianos/uso terapêutico , Antibioticoprofilaxia/métodos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/patologia , Criança , Seguimentos , Hospitalização , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia Mieloide Aguda/patologia , Levofloxacino/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Prognóstico , Anos de Vida Ajustados por Qualidade de Vida
6.
Burns ; 46(4): 817-824, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32291114

RESUMO

BACKGROUND: Profound differences exist in the cost of burn care globally, thus we aim to investigate the affected factors and to delineate a strategy to improve the cost-effectiveness of burn management. METHODS: A retrospective analysis of 66 patients suffering from acute burns was conducted from 2013 to 2015. The average age was 26.7 years old and TBSA was 42.1% (±25.9%). We compared the relationship between cost and clinical characteristics. RESULTS: The estimated cost of acute burn care with the following formula (10,000 TWD) = -19.80 + (2.67 × percentage of TBSA) + (124.29 × status of inhalation injury) + (147.63 × status of bacteremia) + (130.32 × status of respiratory tract infection). CONCLUSION: The majority of the cost were associated with the use of antibiotics and burns care. Consequently, it is crucial to prevent nosocomial infection in order to promote healthcare quality and reduce in-hospital costs.


Assuntos
Antibacterianos/economia , Bacteriemia/economia , Queimaduras/economia , Infecção Hospitalar/economia , Custos de Cuidados de Saúde , Pneumonia Associada à Ventilação Mecânica/economia , Infecção dos Ferimentos/economia , Adolescente , Adulto , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/prevenção & controle , Superfície Corporal , Queimaduras/patologia , Queimaduras/terapia , Custos e Análise de Custo , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/prevenção & controle , Gerenciamento Clínico , Feminino , Humanos , Tempo de Internação/economia , Masculino , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Pneumonia Associada à Ventilação Mecânica/prevenção & controle , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/economia , Infecções Respiratórias/prevenção & controle , Estudos Retrospectivos , Lesão por Inalação de Fumaça , Taiwan , Infecção dos Ferimentos/tratamento farmacológico , Infecção dos Ferimentos/prevenção & controle , Adulto Jovem
7.
Pediatr Infect Dis J ; 39(9): 781-788, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32221163

RESUMO

OBJECTIVE: To evaluate the national trends in pediatric severe sepsis in the United States from 2003 to 2014. STUDY DESIGN: For this study, we included nonoverlapping years of Kids Inpatient database and National Inpatient Sample database while including hospitalizations of children between 1 and 20 years of age from more than 4200 hospitals across the United States. We identified patient hospitalizations with severe sepsis using specific ICD codes and modified Angus Criteria. Trend analysis of various factors associated with severe sepsis was calculated using the Cochrane-Armitage test. Associated foci of infection and comorbid conditions were identified using specific ICD codes, and a multivariate regression analysis with death as outcome variable was done to evaluate for in hospital predictors of mortality. RESULTS: Totally, 109,026 episodes of severe sepsis were identified during the study period between 2003 and 2014. Incidence of severe sepsis hospitalizations increased by 2.5 times (0.64-1.57 per 10,000 population) over the study period with notable concurrent significant decrease in mortality by more than 50%. Lower age, African American, Hispanic ethnicity, complex neurologic conditions, infective endocarditis, immunodeficient states including primary immunodeficiency disorder, HIV, burns, malignancy and transplant status are associated with mortality. There is a significant increase in use of healthcare resources (P < 0.001) with mean charges of 94,966$ despite a notable decrease in mean length of stay (22 vs. 16 days, P < 0.001) over the study period. CONCLUSION: Incidence of pediatric severe sepsis is high leading to a significant use of healthcare resources. This study provides a detailed analysis of associated inpatient factors and comorbidities associated with mortality.


Assuntos
Bacteriemia/epidemiologia , Mortalidade Hospitalar/tendências , Pacientes Internados/estatística & dados numéricos , População , Sepse/epidemiologia , Sepse/mortalidade , Adolescente , Bacteriemia/economia , Bacteriemia/mortalidade , Bactérias/classificação , Bactérias/isolamento & purificação , Bactérias/patogenicidade , Criança , Pré-Escolar , Comorbidade , Bases de Dados Factuais , Feminino , Hospitais/estatística & dados numéricos , Humanos , Incidência , Lactente , Masculino , Fatores de Risco , Sepse/economia , Sepse/microbiologia , Estados Unidos/epidemiologia , Adulto Jovem
8.
PLoS One ; 15(1): e0227772, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31978169

RESUMO

Non-implanted central vascular catheters (CVC) are frequently required for therapy in hospitalized patients with hematological malignancies or solid tumors. However, CVCs may represent a source for bloodstream infections (central line-associated bloodstream infections, CLABSI) and, thus, may increase morbidity and mortality of these patients. A retrospective cohort study over 3 years was performed. Risk factors were determined and evaluated by a multivariable logistic regression analysis. Healthcare costs of CLABSI were analyzed in a matched case-control study. In total 610 patients got included with a CLABSI incidence of 10.6 cases per 1,000 CVC days. The use of more than one CVC per case, CVC insertion for conditioning for stem cell transplantation, acute myeloid leukemia, leukocytopenia (≤ 1000/µL), carbapenem therapy and pulmonary diseases were independent risk factors for CLABSI. Hospital costs directly attributed to the onset of CLABSI were 8,810 € per case. CLABSI had a significant impact on the overall healthcare costs. Knowledge about risk factors and infection control measures for CLABSI prevention is crucial for best clinical practice.


Assuntos
Bacteriemia/epidemiologia , Infecções Relacionadas a Cateter/epidemiologia , Cateterismo Venoso Central/efeitos adversos , Infecção Hospitalar/epidemiologia , Custos de Cuidados de Saúde/estatística & dados numéricos , Adulto , Fatores Etários , Bacteriemia/economia , Bacteriemia/microbiologia , Bactérias/isolamento & purificação , Estudos de Casos e Controles , Infecções Relacionadas a Cateter/economia , Infecções Relacionadas a Cateter/microbiologia , Cateterismo Venoso Central/instrumentação , Cateteres Venosos Centrais/efeitos adversos , Infecção Hospitalar/economia , Infecção Hospitalar/microbiologia , Feminino , Neoplasias Hematológicas/terapia , Hospitalização/economia , Hospitalização/estatística & dados numéricos , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco
9.
Infect Control Hosp Epidemiol ; 41(3): 342-354, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31898557

RESUMO

OBJECTIVE: To estimate the attributable mortality, length of stay (LOS), and healthcare cost of pediatric and neonatal healthcare-acquired bloodstream infections (HA-BSIs). DESIGN: A systematic review and meta-analysis. METHODS: A systematic search (January 2000-September 2018) was conducted in PubMed, Cochrane, and CINAHL databases. Reference lists of selected articles were screened to identify additional studies. Case-control or cohort studies were eligible for inclusion when full text was available in English and data for at least 1 of the following criteria were provided: attributable or excess LOS, healthcare cost, or mortality rate due to HA-BSI. Study quality was evaluated using the Critical Appraisal Skills Programme Tool (CASP). Study selection and quality assessment were conducted by 2 independent researchers, and a third researcher was consulted to resolve any disagreements. Fixed- or random-effect models, as appropriate, were used to synthesize data. Heterogeneity and publication bias were evaluated. RESULTS: In total, 21 studies were included in the systematic review and 13 studies were included in the meta-analysis. Attributable mean LOS ranged between 4 and 27.8 days; healthcare cost ranged between $1,642.16 and $160,804 (2019 USD) per patient with HA-BSI; and mortality rate ranged between 1.43% and 24%. The pooled mean attributable hospital LOS was 16.91 days (95% confidence interval [CI], 13.70-20.11) and the pooled attributable mortality rate was 8% (95% CI, 6-9). A meta-analysis was not conducted for cost due to lack of eligible studies. CONCLUSIONS: Pediatric HA-BSIs have a significant impact on mortality, LOS, and healthcare cost, further highlighting the need for implementation of HA-BSI prevention strategies.


Assuntos
Bacteriemia , Infecção Hospitalar , Custos de Cuidados de Saúde/estatística & dados numéricos , Tempo de Internação , Sepse , Adulto , Bacteriemia/economia , Bacteriemia/mortalidade , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos de Coortes , Infecção Hospitalar/economia , Infecção Hospitalar/microbiologia , Infecção Hospitalar/mortalidade , Feminino , Humanos , Lactente , Recém-Nascido , Tempo de Internação/economia , Tempo de Internação/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Sepse/economia , Sepse/mortalidade , Adulto Jovem
10.
Am J Infect Control ; 48(5): 560-565, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-31677923

RESUMO

BACKGROUND: In September 2016, the Korean National Health Insurance Service began reimbursing infection control (IC) costs on the condition that a certain number of doctors and full-time nurses for IC be allocated to supported hospitals. We analyzed the impact of the IC cost reimbursement policy on central line-associated bloodstream infections (CLABSIs). METHODS: A before-and-after study that analyzed the CLABSI rate trends between preintervention (January 2016 to February 2017) and intervention (March to December 2017) periods using autoregression time series analysis was performed in intensive care units (ICUs) at a 750-bed, secondary care hospital in Daegu, Republic of Korea. The enhanced IC team visited ICUs daily, monitored the implementation of CLABSI prevention bundles, and educated all personnel involved in catheter insertion and maintenance from March 2017. RESULTS: Autoregressive analysis revealed that the CLABSI rates per month in the preintervention and intervention periods were -0.256 (95% confidence interval, -0.613 to 0.101; P = .15) and -0.602 (95% confidence interval, -0.972 to -0.232; P = .008), respectively. The rates of compliance with maximal barrier precautions significantly improved from the preintervention (36.2%) to the intervention (77.9%) period (χ² test, P < .001). CONCLUSIONS: The IC cost reimbursement policy accelerated the decline in CLABSI rates significantly in monitored ICUs. A nationwide study to evaluate the effectiveness of the IC cost reimbursement policy for various health care-associated infections is warranted.


Assuntos
Bacteriemia/epidemiologia , Infecções Relacionadas a Cateter/epidemiologia , Controle de Infecções/economia , Reembolso de Seguro de Saúde/estatística & dados numéricos , Pacotes de Assistência ao Paciente/economia , Bacteriemia/economia , Bacteriemia/prevenção & controle , Infecções Relacionadas a Cateter/economia , Infecções Relacionadas a Cateter/prevenção & controle , Cateterismo Venoso Central/efeitos adversos , Fidelidade a Diretrizes/economia , Humanos , Unidades de Terapia Intensiva , Análise de Regressão , República da Coreia/epidemiologia
11.
J Appl Lab Med ; 3(4): 617-630, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-31639730

RESUMO

BACKGROUND: For far too long, the diagnosis of bloodstream infections has relied on time-consuming blood cultures coupled with traditional organism identification and susceptibility testing. Technologies to define the culprit in bloodstream infections have gained sophistication in recent years, notably by application of molecular methods. CONTENT: In this review, we summarize the tests available to clinical laboratories for molecular rapid identification and resistance marker detection in blood culture bottles that have flagged positive. We explore the cost-benefit ratio of such assays, covering aspects that include performance characteristics, effect on patient care, and relevance to antibiotic stewardship initiatives. SUMMARY: Rapid blood culture diagnostics represent an advance in the care of patients with bloodstream infections, particularly those infected with resistant organisms. These diagnostics are relatively easy to implement and appear to have a positive cost-benefit balance, particularly when fully incorporated into a hospital's antimicrobial stewardship program.


Assuntos
Gestão de Antimicrobianos/tendências , Bacteriemia/diagnóstico , Hemocultura/métodos , Serviços de Laboratório Clínico/tendências , Fungemia/diagnóstico , Anti-Infecciosos/farmacologia , Anti-Infecciosos/uso terapêutico , Gestão de Antimicrobianos/economia , Gestão de Antimicrobianos/métodos , Bacteriemia/tratamento farmacológico , Bacteriemia/economia , Bacteriemia/microbiologia , Bactérias/genética , Bactérias/isolamento & purificação , Proteínas de Bactérias/genética , Proteínas de Bactérias/isolamento & purificação , Hemocultura/economia , Hemocultura/tendências , Serviços de Laboratório Clínico/economia , Serviços de Laboratório Clínico/organização & administração , Análise Custo-Benefício , DNA Bacteriano/isolamento & purificação , DNA Fúngico/isolamento & purificação , Farmacorresistência Bacteriana/genética , Farmacorresistência Fúngica/genética , Proteínas Fúngicas/genética , Proteínas Fúngicas/isolamento & purificação , Fungemia/tratamento farmacológico , Fungemia/economia , Fungemia/microbiologia , Fungos/genética , Fungos/isolamento & purificação , Técnicas de Genotipagem/economia , Técnicas de Genotipagem/instrumentação , Técnicas de Genotipagem/métodos , Custos de Cuidados de Saúde , Humanos , Testes de Sensibilidade Microbiana/instrumentação , Testes de Sensibilidade Microbiana/métodos , Fatores de Tempo , Tempo para o Tratamento
12.
PLoS One ; 14(9): e0221944, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31504046

RESUMO

INTRODUCTION: Antibiotic resistance poses a threat to public health and healthcare systems. Escherichia coli causes more bacteraemia episodes in England than any other bacterial species. This study aimed to estimate the burden of E. coli bacteraemia and associated antibiotic resistance in the secondary care setting. MATERIALS AND METHODS: This was a retrospective cohort study, with E. coli bacteraemia as the main exposure of interest. Adult hospital in-patients, admitted to acute NHS hospitals between July 2011 and June 2012 were included. English national surveillance and administrative datasets were utilised. Cox proportional hazard, subdistribution hazard and multistate models were constructed to estimate rate of discharge, rate of in-hospital death and excess length of stay, with a unit bed day cost applied to the latter to estimate cost burden from the healthcare system perspective. RESULTS: 14,042 E. coli bacteraemia and 8,919,284 non-infected inpatient observations were included. E. coli bacteraemia was associated with an increased rate of in-hospital death across all models, with an adjusted subdistribution hazard ratio of 5.88 (95% CI: 5.62-6.15). Resistance was not found to be associated with in-hospital mortality once adjusting for patient and hospital covariates. However, resistance was found to be associated with an increased excess length of stay. This was especially true for third generation cephalosporin (1.58 days excess length of stay, 95% CI: 0.84-2.31) and piperacillin/tazobactam resistance (1.23 days (95% CI: 0.50-1.95)). The annual cost of E. coli bacteraemia was estimated to be £14,346,400 (2012 £), with third-generation cephalosporin resistance associated with excess costs per infection of £420 (95% CI: 220-630). CONCLUSIONS: E. coli bacteraemia places a statistically significant burden on patient health and the hospital sector in England. Resistance to front-line antibiotics increases length of stay; increasing the cost burden of such infections in the secondary care setting.


Assuntos
Bacteriemia/economia , Efeitos Psicossociais da Doença , Farmacorresistência Bacteriana , Infecções por Escherichia coli/economia , Bacteriemia/epidemiologia , Inglaterra , Infecções por Escherichia coli/epidemiologia , Custos Hospitalares , Hospitais/estatística & dados numéricos , Humanos
13.
BMC Infect Dis ; 19(1): 650, 2019 Jul 22.
Artigo em Inglês | MEDLINE | ID: mdl-31331272

RESUMO

BACKGROUND: This study aimed to evaluate the oral switch (OS) stewardship intervention in the intensive care unit (ICU). METHODS: This was a retrospective study with a convenience sample in two Brazilian ICUs from different hospitals in patients with sepsis receiving antibiotic therapy. The stewardship intervention included OS in patients diagnosed with sepsis when clinical stability was achieved. The primary outcome was overall mortality. Other variables evaluated were as follows: cost of antimicrobial treatment, daily costs of intensive care, acute kidney injury, and length of stay. RESULTS: There was no difference in mortality between the OS and non-OS groups (p = 0.06). Length of stay in the ICU (p = 0.029) was shorter and acute kidney injury incidence (p = 0.032) and costs of antimicrobial therapy (p < 0.001) were lower in the OS group. CONCLUSION: OS stewardship programs in the ICU may be considered a safe strategy. Switch therapy reduced the cost and shortened the length of stay in ICUs.


Assuntos
Antibacterianos/administração & dosagem , Bacteriemia/tratamento farmacológico , Bacteriemia/mortalidade , Injúria Renal Aguda/induzido quimicamente , Administração Intravenosa , Administração Oral , Idoso , Antibacterianos/economia , Antibacterianos/uso terapêutico , Bacteriemia/economia , Brasil , Custos e Análise de Custo , Estudos Transversais , Feminino , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
14.
Clin Nutr ESPEN ; 30: 100-106, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30904208

RESUMO

BACKGROUND AND AIMS: Complications such as blood stream infections (BSI) have been observed with the administration of parenteral nutrition (PN). Prior published studies reported the incidence of BSI for inpatient hospitalizations by comparing patients treated with custom compounded parenteral nutrition to those treated with premixed multichamber bag (MCB) formulations. Previous publications grouped patients treated with MCBs into a single category and no distinction was made between patients receiving only a MCB and those receiving a MCB supplemented with manual additions. This Study aims to assess differences in risk of blood stream infection, cost, and clinical outcomes among patients receiving multichamber bag parenteral nutrition products only (MCB-only), MCB with additions (MCB-addition), and compounded (COM) PN products using seven years of Premier Healthcare Data from 688 hospitals in the United States of America. METHODS: Adult inpatients who were discharged between 01/01/2008 and 12/31/2014, had a hospital length of stay ≥3 days and received PN during the index hospitalization were analyzed. PN preparation method was determined by billing charge descriptions. BSI was defined as having primary or secondary ICD-9 diagnosis codes of 038.x (septicemia), 995.91 (sepsis), 995.92 (severe sepsis), and 790.7 (bacteremia). Multivariable regression models were used to assess effect of PN preparation on patient outcomes, adjusting for confounders. RESULTS: 84,564 patients were analyzed (MCB-only: 6.3%; MCB-addition: 14.8%; COM: 78.9%). Multivariable analysis indicated that compared to COM group, MCB-addition group had similar risk of BSI (7.0% vs. 6.8%, P > 0.05) and a 2.7% lower average total hospitalization cost ($28,072 vs. $28,861, P < 0.05) but had a higher PN treatment cost ($1135 vs. $1,031, P < 0.05) and a higher percentage of being discharged to rehabilitation or other acute care facilities (39.4% vs. 31.1%, P < 0.05). MCB-only group had lower risk of BSI and hospitalization cost. CONCLUSIONS: In the U.S., compounded PN is the most commonly used in clinical practice followed by MCB with additions. MCB-addition group had similar BSI risk with COM. The slightly lower overall cost in MCB-addition group may be offset by higher post-hospitalization care cost to providers and payers under bundled payment methods in the U.S.


Assuntos
Bacteriemia/epidemiologia , Soluções de Nutrição Parenteral/efeitos adversos , Nutrição Parenteral Total/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Bacteriemia/economia , Bacteriemia/etiologia , Estudos Transversais , Feminino , Humanos , Revisão da Utilização de Seguros , Unidades de Terapia Intensiva , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Estados Unidos/epidemiologia , Adulto Jovem
15.
J Infect Public Health ; 12(3): 372-379, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30616938

RESUMO

BACKGROUND AND OBJECTIVE: Central line-associated bloodstream infections (CLABSIs) are the most frequent pediatric hospital-acquired infections and are associated with significant morbidity and healthcare costs. The aim of our study was to determine the attributable length of stay (LOS) and cost for CLABSIs in pediatric patients in Greece, for which there is currently a paucity of data. METHODS: A retrospective matched-cohort study was performed in two tertiary pediatric hospitals. Inpatients with a central line in neonatal and pediatric intensive care units, hematology/oncology units, and a bone marrow transplantation unit between June 2012 and June 2015 were eligible. Patients with confirmed CLABSI were enrolled on the day of the event and were matched (1:1) to patients without CLABSI (non-CLABSIs) by hospital, unit, and LOS prior to study enrollment (188 children enrolled, 94 CLABSIs). The primary outcome measure was the attributable LOS and cost. Baseline demographic and clinical characteristics were recorded. Attributable outcomes were calculated as the differences in estimates of outcomes between CLABSIs and non-CLABSIs, after adjustment for propensity score and potential confounders. RESULTS: There were no differences between the two groups regarding their baseline characteristics. After adjustment for age, gender, matching characteristics, central line management after study enrollment, and propensity score, the mean LOS and cost were 57.5days and €31,302 in CLABSIs versus 36.6days and €17,788 in non-CLABSIs. Overall, a CLABSI was associated with a mean (95% CI) adjusted attributable LOS and cost of 21days (7.3-34.8) and €13,727 (5,758-21,695), respectively. No significant difference was detected in LOS and cost by hospitalization unit. CONCLUSIONS: CLABSIs were found to impose a significant economic burden in Greece, a finding that highlights the importance of implementing CLABSI prevention strategies.


Assuntos
Bacteriemia/epidemiologia , Infecções Relacionadas a Cateter/epidemiologia , Tempo de Internação , Bacteriemia/economia , Bacteriemia/prevenção & controle , Infecções Relacionadas a Cateter/economia , Infecções Relacionadas a Cateter/prevenção & controle , Serviços de Saúde da Criança/economia , Feminino , Grécia/epidemiologia , Custos de Cuidados de Saúde , Hospitais Pediátricos , Humanos , Lactente , Recém-Nascido , Masculino , Estudos Retrospectivos
16.
PLoS One ; 14(1): e0210271, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30615655

RESUMO

BACKGROUND: Beta-lactams are the mainstay for treating methicillin-susceptible Staphylococcus aureus (MSSA) infections complicated by bacteremia due to superior outcomes compared with vancomycin. With approximately 11% of inpatients reporting a penicillin (PCN) allergy, many patients receive suboptimal treatment for MSSA bacteremia. OBJECTIVE: Evaluate the cost-effectiveness of penicillin skin testing (PST) in adult patients with self-reported PCN allergy in an inpatient setting undergoing treatment for MSSA bacteremia. METHODS: A decision analytic model was developed comparing an acute care PST intervention to a scenario with no confirmatory allergy testing. The primary outcome was the incremental cost-effectiveness ratio (ICER) from the health-sector perspective over a 1-year time horizon using quality-adjusted life years (QALYs) as the measure for effectiveness. One-way and probabilistic sensitivity analyses were conducted to assess the uncertainty of the ICER estimation. RESULTS: Over a 1-year time horizon, PST services applied to all MSSA bacteremia patients reporting a PCN-allergy would result in a cost per patient of $12,559 and 0.73 QALYs while no PST services would have a higher cost per patient of $13,219 and 0.66 QALYs per patient. This resulted in a cost-effectiveness estimate of -$9,429 per QALY gained. Varying the cost of implementing PST services determined a break-even point of $959.98 where any PST cost less than this amount would actually be cost saving. CONCLUSIONS: Patients reporting a PCN allergy on admission may receive sub-optimal alternative therapies to beta-lactams, such as vancomycin, for MSSA bacteremia. This economic analysis demonstrates that inpatient PST services confirming PCN allergy are cost-effective for patients with MSSA bacteremia.


Assuntos
Antibacterianos/efeitos adversos , Bacteriemia/economia , Análise Custo-Benefício , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/economia , Penicilinas/efeitos adversos , Testes Cutâneos/economia , Infecções Estafilocócicas/complicações , Adulto , Bacteriemia/diagnóstico , Bacteriemia/epidemiologia , Bacteriemia/microbiologia , Humanos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia
17.
Korean J Intern Med ; 34(6): 1347-1362, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29347812

RESUMO

BACKGROUND/AIMS: Methicillin-resistant Staphylococcus aureus (MRSA) is highly prevalent in hospitals, and has recently emerged in the community. The impact of methicillin-resistance on mortality and medical costs for patients with S. aureus bacteremia (SAB) requires reevaluation. METHODS: We searched studies with SAB or endocarditis using electronic databases including Ovid-Medline, Embase-Medline, and Cochrane Library, as well as five local databases for published studies during the period January 2000 to September 2011. RESULTS: A total of 2,841 studies were identified, 62 of which involved 17,563 adult subjects and were selected as eligible. A significant increase in overall mortality associated with MRSA, compared to that with methicillin-susceptible S. aureus (MSSA), was evidenced by an odds ratio (OR) of 1.95 (95% confidence interval [CI], 1.73 to 2.21; p < 0.01). In 13 endocarditis studies, MRSA increased the risk of mortality, with an OR of 2.65 (95% CI, 1.46 to 4.80). When three studies, which compared mortality rates between CA-MRSA and CA-MSSA, were combined, the risk of methicillin-resistance increased 3.23-fold compared to MSSA (95% CI, 1.25 to 8.34). The length of hospital stay in the MRSA group was 10 days longer than that in the MSSA group (95% CI, 3.36 to 16.70). Of six studies that reported medical costs, two were included in the analysis, which estimated medical costs to be $9,954.58 (95% CI, 8,951.99 to 10,957.17). CONCLUSION: MRSA is still associated with increased mortality, longer hospital stays and medical costs, compared with MSSA in SAB in studies published since the year 2000.


Assuntos
Bacteriemia/terapia , Endocardite Bacteriana/terapia , Staphylococcus aureus Resistente à Meticilina/patogenicidade , Infecções Estafilocócicas/terapia , Bacteriemia/economia , Bacteriemia/microbiologia , Bacteriemia/mortalidade , Endocardite Bacteriana/economia , Endocardite Bacteriana/microbiologia , Endocardite Bacteriana/mortalidade , Custos de Cuidados de Saúde , Humanos , Tempo de Internação , Medição de Risco , Fatores de Risco , Infecções Estafilocócicas/economia , Infecções Estafilocócicas/microbiologia , Infecções Estafilocócicas/mortalidade , Fatores de Tempo , Resultado do Tratamento
18.
Acad Pediatr ; 19(2): 209-215, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30415079

RESUMO

BACKGROUND: Ninety percent of infants 29 to 60 days old presenting to the emergency department with fever and urinary tract infection are admitted due to fear of concomitant bacteremia. Many of these infants are at low risk for bacteremia and can be safely discharged with no heightened risk of adverse events. This study sought to estimate the potential savings from outpatient management of low-risk infants. METHODS: A comparative cost analysis was performed using bacteremia probability estimates from a previously published prediction model. We estimated costs using a national pediatric database coupled with retrospective chart review of infants who presented to our emergency department between 2011 and 2015. RESULTS: The relative cost savings for the discharge strategy were $80,333 ($19,127 vs $99,460; 80% savings) for each patient with bacteremia and $257,073 per 100 patients overall. Similar savings were found for charges-$304,949 ($71,421 vs $376,371; 80%) for each patient with bacteremia and $975,838 per 100 patients. Our institutional reimbursements provided an estimated savings of $148,924 ($73,280 vs. $222,204; 67%) and $476,533 per 100 patients overall. CONCLUSIONS: The relative cost savings from discharging rather than admitting low-risk infants with febrile urinary tract infection were significant, even accounting for expenditures associated with the return emergency room visit of initially discharged bacteremic patients. These savings are achievable without an increase in adverse events. Similar outcomes were demonstrated for hospital charges and reimbursements, further strengthening these results. This study emphasizes how risk stratification in clinical decision-making can lead to substantial cost savings without compromising patient outcomes.


Assuntos
Assistência Ambulatorial/economia , Bacteriemia/epidemiologia , Febre/terapia , Hospitalização/economia , Infecções Urinárias/terapia , Bacteriemia/economia , Bacteriemia/terapia , Tomada de Decisão Clínica , Custos e Análise de Custo , Serviço Hospitalar de Emergência , Feminino , Febre/economia , Gastos em Saúde , Humanos , Lactente , Masculino , Alta do Paciente , Estudos Retrospectivos , Medição de Risco , Infecções Urinárias/economia
19.
Health Qual Life Outcomes ; 16(1): 198, 2018 Oct 11.
Artigo em Inglês | MEDLINE | ID: mdl-30305105

RESUMO

BACKGROUND: Central venous catheters (CVC) have been widely used for patients with severe conditions. However, they increase the risk of catheter-related bloodstream infection (CRBSI), which is associated with high economic burden. Until now, no study has focused on the cost attributable to CRBSI in China, and data on its economic burden are unavailable. The aim of this study was to assess the cost attributable to CRBSI and its influencing factors. METHODS: A retrospective matched case-control study and multivariate analysis were conducted in a tertiary hospital, with 94 patients (age ≥ 18 years old) from January 2011 to November 2015. Patients with CRBSI were matched to those without CRBSI by age, principal diagnosis, and history of surgery. The difference in cost between the case group and control group during the hospitalization was calculated as the cost attributable to CRBSI, which included the total cost and five specific cost categories: drug, diagnostic imaging, laboratory testing, health care technical services, and medical material. The relation between the total cost attributable to CRBSI and its influencing factors such as demographic characteristics, diagnosis and treatment, and pathogenic microorganism, was analysed with a general linear model (GLM). RESULTS: The total cost attributable to CRBSI was $3528.6, and the costs of specific categories including drugs, diagnostic imaging, laboratory testing, health care technical services, and medical material, were $2556.4, $112.1, $321.7, $268.7, $276.5, respectively. GLM analysis indicated that the total cost was associated with the intensive care unit (ICU), pathogenic microorganism, age, and catheter number, according to the sequence of standardized estimate (ß). ICU contributed the most to the model R-square. CONCLUSION: Central venous catheter-related bloodstream infection represents a great economic burden for patients. More attentions should be paid to further prevent and control this infection in China.


Assuntos
Bacteriemia/economia , Infecções Relacionadas a Cateter/economia , Cateteres Venosos Centrais/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Custos Hospitalares/estatística & dados numéricos , Adulto , Idoso , Bacteriemia/epidemiologia , Bacteriemia/terapia , Estudos de Casos e Controles , Infecções Relacionadas a Cateter/epidemiologia , Infecções Relacionadas a Cateter/terapia , Cateteres Venosos Centrais/estatística & dados numéricos , China , Feminino , Humanos , Unidades de Terapia Intensiva/economia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Centros de Atenção Terciária/economia , Adulto Jovem
20.
Aliment Pharmacol Ther ; 48(4): 410-422, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29978597

RESUMO

BACKGROUND: The catheter lock solutions 2% taurolidine and 0.9% saline are both used to prevent catheter-related bloodstream infections (CRBSIs) in home parenteral nutrition patients. AIMS: To compare the effectiveness and safety of taurolidine and saline. METHODS: This multicentre double-blinded trial randomly assigned home parenteral nutrition patients to use either 2% taurolidine or 0.9% saline for 1 year. Patients were stratified in a new catheter group and a pre-existing catheter group. Primary outcome was the rate of CRBSIs/1000 catheter days in the new catheter group and pre-existing catheter group, separately. RESULTS: We randomised 105 patients, of which 102 were analysed as modified intention-to-treat population. In the new catheter group, rates of CRBSIs/1000 catheter days were 0.29 and 1.49 in the taurolidine and saline arm respectively (relative risk, 0.20; 95% CI, 0.04-0.71; P = 0.009). In the pre-existing catheter group, rates of CRBSIs/1000 catheter days were 0.39 and 1.32 in the taurolidine and saline arm respectively (relative risk, 0.30; 95% CI, 0.03-1.82; P = 0.25). Excluding one outlier patient in the taurolidine arm, mean costs per patient were $1865 for taurolidine and $4454 for saline (P = 0.03). Drug-related adverse events were rare and generally mild. CONCLUSIONS: In the new catheter group, taurolidine showed a clear decrease in CRBSI rate. In the pre-existing catheter group, no superiority of taurolidine could be demonstrated, most likely due to underpowering. Overall, taurolidine reduced the risk for CRBSIs by more than four times. Given its favourable safety and cost profile, taurolidine locking should be considered as an additional strategy to prevent CRBSIs. TRIAL REGISTRATION: Clinicaltrials.gov, identifier: NCT01826526.


Assuntos
Nutrição Parenteral no Domicílio/métodos , Solução Salina/administração & dosagem , Taurina/análogos & derivados , Tiadiazinas/administração & dosagem , Adulto , Idoso , Bacteriemia/economia , Bacteriemia/epidemiologia , Bacteriemia/etiologia , Infecções Relacionadas a Cateter/economia , Infecções Relacionadas a Cateter/epidemiologia , Infecções Relacionadas a Cateter/prevenção & controle , Método Duplo-Cego , Estudos de Equivalência como Asunto , Feminino , Custos de Cuidados de Saúde , Recursos em Saúde/economia , Recursos em Saúde/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Nutrição Parenteral no Domicílio/efeitos adversos , Nutrição Parenteral no Domicílio/economia , Nutrição Parenteral no Domicílio/estatística & dados numéricos , Solução Salina/efeitos adversos , Solução Salina/economia , Taurina/administração & dosagem , Taurina/efeitos adversos , Taurina/economia , Tiadiazinas/efeitos adversos , Tiadiazinas/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...